Breast cancer is the second leading cause of death for women worldwide. The
heterogeneity of this disease presents a big challenge in its therapeutic management …

Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Background Adjuvant abemaciclib plus endocrine therapy previously showed a significant
improvement in invasive disease-free survival and distant relapse-free survival in hormone …

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Background Adjuvant abemaciclib combined with endocrine therapy (ET) previously
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …

PURPOSE About one third of patients with hormone receptor–positive, human epidermal
growth factor receptor 2–negative breast cancer who have residual invasive disease after …

Abstract Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-
negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which …

PURPOSE Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced
breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine …